Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The results suggest that previous infection, together with vaccination, offers strong protection against the original Covid-19 strain.

Vaccination 59

Vaccination Vaccine Development Immune Response 59

Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccination 52

Vaccination Vaccine Development Bacterium 52

Pharmaceutical Technology

SEPTEMBER 7, 2022

Indian company Bharat Biotech International has secured approval from Central Drugs Standard Control Organisation (CDSCO) under Restricted Use in Emergency Situation for its intranasal Covid-19 vaccine, iNCOVACC (BBV154), for usage in people aged 18 years and older. It is formulated to permit intranasal delivery via nasal drops.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

Pharmaceutical Technology

APRIL 13, 2023

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world. Julian Naidoo, CEO of Rubic One Health.

Production 279

Production Vaccination Vaccine Protein 279

Pharmaceutical Technology

DECEMBER 2, 2022

India’s Central Drugs Standard Control Organisation (CDSCO) has granted approval for Bharat Biotech’s BBV154 vaccine for treating Covid-19. BBV154 is claimed to be the first intra-nasal vaccine for Covid-19 in the world.

Vaccination 217

Vaccination Vaccine Licensing Licensing 217

Pharmaceutical Technology

MAY 23, 2023

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. The plentiful supply of QS-21 enables the production of next-generation adjuvant systems for new vaccine development.”

Production 240

Production Vaccination Vaccine Life Science 240

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Innovative new vaccines are being created more rapidly than ever before.

Vaccination 97

Vaccination Vaccine Development Marketing 97

Drug Discovery World

FEBRUARY 20, 2024

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. Licensing for human use Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Vaccination 52

Vaccination Vaccine Development Immune Response 52

XTalks

NOVEMBER 9, 2020

SARS-CoV-2 Vaccines Inch Towards Regulatory Approval. Over the past month or so, investigators have been amassing data on SARS-CoV-2 candidate vaccines as quickly as possible and some of that data is making its way—ever so much more slowly—through regulatory agencies for official scrutiny.

Vaccination 105

Vaccination Vaccine Development Drugs 105

Pharmaceutical Technology

DECEMBER 7, 2022

Health Canada has granted approval for a supplement to a New Drug Submission (sNDS) of Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted), Nuvaxovid (NVX-CoV2373), for use in adolescents aged 12 to 17 years. The trial is designed to analyse the safety and effectiveness of the vaccine.

Vaccination 264

Vaccination Vaccine Protein Clinical Trials 264

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.

Engineer 262

Engineer Vaccination Vaccine Clinical Trials 262

Pharmaceutical Technology

FEBRUARY 23, 2023

GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. The company provides end-to-end contract development and manufacturing organisation (CDMO) services from the discovery to the commercialisation of drugs.

Vaccination 289

Vaccination Vaccine Gene Therapy Manufacturing 289

Pharmaceutical Technology

NOVEMBER 1, 2022

What is Research and Development (R&D)? This category includes organisations that have demonstrated a commitment to the research and development of new products and/or new processes. This category highlights companies that have conducted research into the use of AI and technology for the development of new treatments.

Development 228

Development Research Production Vaccination 228

Pharmaceutical Technology

JULY 1, 2022

Some months after the first Covid-19 vaccines became available, the World Health Organization (WHO) set a target of vaccinating 70% of each country’s population by the end of June 2022. The post Magazine-How delays derailed Covid-19 vaccination in Africa appeared first on Pharmaceutical Technology.

Vaccination 277

Vaccination Vaccine Big Data Development 277

Bio Pharma Dive

JANUARY 10, 2023

Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial.

Trials 285

Trials Drug Trials Development Vaccination 285

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development 59

Development Drugs Genome Genomics 59

Pharmaceutical Technology

OCTOBER 31, 2022

After decades of setbacks, the respiratory syncytial virus (RSV) vaccine field has bounced back with positive Phase III trial results in older adults. There are currently five players in the race, with vaccines in Phase III of development from GlaxoSmithKline (GSK) , Pfizer , Johnson & Johnson , Moderna and Bavarian Nordic.

Vaccination 338

Vaccination Vaccine Marketing Containment 338

Drug Discovery World

DECEMBER 11, 2023

Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 Naobios will manufacture a human viral challenge agent that will be used to evaluate the effectiveness of vaccines in preventing infections and to accelerate the vaccine development process.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

Last year was a positive year for biopharmaceutical companies, particularly those with Covid-19 vaccines. As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. YoY revenue growth.

Vaccination 272

Vaccination Vaccine Sales Generic Drugs 272

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The post Merck and Moderna to develop a personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 97

Vaccination Vaccine Development Clinical Development 97

Pharmaceutical Technology

FEBRUARY 14, 2023

The US Department of Health and Human Services (HHS) and the Department of Defense have modified their existing agreement with Novavax to secure additional doses of the Covid-19 vaccine, Adjuvanted (NVX-CoV2373). million additional doses of its Covid-19 vaccine. It was developed using the recombinant nanoparticle technology of Novavax.

Vaccination 162

Vaccination Vaccine Protein Engineer 162

Pharmaceutical Technology

AUGUST 1, 2022

Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.

Vaccination 289

Vaccination Vaccine Gene Therapy RNA 289

BioPharma Reporter

NOVEMBER 30, 2023

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 Department of Defense, to develop technologies for needle-free vaccines. million in new funding from the U.S.

Development 52

Development Vaccination Vaccine Drugs 52

BioPharma Reporter

NOVEMBER 30, 2023

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 Department of Defense, to develop technologies for needle-free vaccines. million in new funding from the U.S.

Development 52

Development Vaccination Vaccine Drugs 52

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccination 263

Vaccination Vaccine Clinical Trials Clinical Trials 263

VirTrial

OCTOBER 25, 2023

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Drug Discovery World

DECEMBER 6, 2022

As a result of clear US Food and Drug Administration (FDA) guidelines, the leading vaccine development programmes for Covid-19 were all remarkably similar. For example, care homes could have been selected at random to receive a Covid-19 vaccine, since not all care homes could be visited at once.

Development 98

Development Drugs Vaccination Vaccine 98

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development 52

Development Drugs Genome Genomics 52

Drug Discovery World

JUNE 3, 2024

Thousands of cancer patients in England are set to gain fast-tracked access to trials of mRNA personalised cancer vaccines following the launch of an NHS trial ‘matchmaking’ service to help find new life-saving treatments.

Vaccination 59

Vaccination Vaccine Trials Genome 59

Pharmaceutical Technology

JULY 13, 2022

Merck (MSD outside North America) and Orion have entered an international agreement to develop and market the latter’s investigational candidate ODM-208 to treat metastatic castration-resistant prostate cancer (mCRPC). Orion discovered and developed ODM-208 to treat hormone-dependent cancers, such as prostate cancer.

Development 264

Development Hormones Production Marketing 264

pharmaphorum

DECEMBER 1, 2021

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.

Vaccination 104

Vaccination Vaccine Development Hormones 104

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Spikevax is an mRNA vaccine that is approved in 20 geographies including the US, EU, and, the UK. The vaccine first gained Emergency Use Approval in December 2020 in response to the Covid-19 pandemic.

Sales 147

Sales Vaccination Vaccine Marketing 147

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” It showed that the 2.5-year

Vaccination 59

Vaccination Vaccine Clinical Trials Clinical Trials 59

Pharma Mirror

OCTOBER 16, 2023

by Carrie Taylor, Director of Research & Development of BOCSCI. Globally, the COVID-19 pandemic has significantly accelerated the development of mRNA technology platforms and mRNA industry chains.

Immune Response 130

Immune Response Drugs Protein Vaccination 130

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has approved Pfizer’s 20-valent pneumococcal conjugate vaccine, PREVNAR 20 , to prevent invasive pneumococcal disease (IPD) in infants and children aged six weeks to 17 years. PREVNAR 20 has been developed on the basis of Pfizer’s approved PREVNAR 13 vaccine.

Vaccination 147

Vaccination Vaccine FDA Approval Trials 147

Bio Pharma Dive

APRIL 15, 2021

The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines.

Drugs 321

Drugs Vaccination Vaccine Medicine 321

Drug Discovery World

MAY 13, 2024

Reece Armstrong speaks to Melanie Adams-Cioaba , Senior Director and General Manager of pharma (cryo-EM), Thermo Fisher Scientific about advances in vaccine design. Using structural biology as central to vaccine design and development, and to drug discovery more generally, is what we mean by “rational design.”

Vaccination 59

Vaccination Vaccine Protein Antibody 59